These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

337 related items for PubMed ID: 38477313

  • 21. Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug-drug interaction study.
    Jakate A, Blumenfeld AM, Boinpally R, Butler M, Borbridge L, Contreras-De Lama J, McGeeney D, Periclou A, Lipton RB.
    Headache; 2021 Apr; 61(4):642-652. PubMed ID: 33818780
    [Abstract] [Full Text] [Related]

  • 22. Emerging drugs for the preventive treatment of migraine: a review of CGRP monoclonal antibodies and gepants trials.
    Silvestro M, Orologio I, Siciliano M, Trojsi F, Tessitore A, Tedeschi G, Russo A.
    Expert Opin Emerg Drugs; 2023 Dec; 28(2):79-96. PubMed ID: 37185047
    [Abstract] [Full Text] [Related]

  • 23. Targeting CGRP for migraine treatment: mechanisms, antibodies, small molecules, perspectives.
    De Matteis E, Guglielmetti M, Ornello R, Spuntarelli V, Martelletti P, Sacco S.
    Expert Rev Neurother; 2020 Jun; 20(6):627-641. PubMed ID: 32434430
    [Abstract] [Full Text] [Related]

  • 24. Rimegepant: acute treatment for migraine headaches.
    Peters GL, Hennessey EK.
    Pain Manag; 2021 May; 11(3):259-266. PubMed ID: 33550872
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Small molecule CGRP receptor antagonists for the preventive treatment of migraine: A review.
    Dos Santos JBR, da Silva MRR.
    Eur J Pharmacol; 2022 May 05; 922():174902. PubMed ID: 35358493
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Role of CGRP in Migraine.
    Edvinsson L.
    Handb Exp Pharmacol; 2019 May 05; 255():121-130. PubMed ID: 30725283
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trial.
    Tassorelli C, Nagy K, Pozo-Rosich P, Lanteri-Minet M, Sacco S, Nežádal T, Guo H, De Abreu Ferreira R, Forero G, Trugman JM.
    Lancet Neurol; 2024 Apr 05; 23(4):382-392. PubMed ID: 38364831
    [Abstract] [Full Text] [Related]

  • 33. Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans.
    de Vries T, Villalón CM, MaassenVanDenBrink A.
    Pharmacol Ther; 2020 Jul 05; 211():107528. PubMed ID: 32173558
    [Abstract] [Full Text] [Related]

  • 34. Raynaud's phenomenon associated with calcitonin gene-related peptide receptor antagonists case report.
    Bedrin K, Ailani J, Dougherty C.
    Headache; 2022 Nov 05; 62(10):1419-1423. PubMed ID: 36426766
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Comparative Efficacy and Safety of Five Anti-calcitonin Gene-related Peptide Agents for Migraine Prevention: A Network Meta-analysis.
    Sun W, Cheng H, Xia B, Liu X, Li Y, Wang X, Liu C.
    Clin J Pain; 2023 Oct 01; 39(10):560-569. PubMed ID: 37278480
    [Abstract] [Full Text] [Related]

  • 38. An observational study on monoclonal antibodies against calcitonin-gene-related peptide and its receptor.
    Schiano di Cola F, Bolchini M, Ceccardi G, Caratozzolo S, Liberini P, Rao R, Padovani A.
    Eur J Neurol; 2023 Jun 01; 30(6):1764-1773. PubMed ID: 36856538
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Comparative Efficacy of Oral Calcitonin-Gene-Related Peptide Antagonists for the Treatment of Acute Migraine: Updated Meta-analysis.
    Ha DK, Kim MJ, Han N, Kwak JH, Baek IH.
    Clin Drug Investig; 2021 Feb 01; 41(2):119-132. PubMed ID: 33426614
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.